Stryker reports 9.40 percent revenue growth. Stryker stock sits 3.44 percent below target

Published on 10/26/2026 at 17:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted earnings per share rose 17.90 percent in Q2 2026. Stryker stock costs EUR 273.20 on October 26, 2026, down 0.69 percent versus Xetra close.

Revenue growth and valuation

Stryker reported 9.40 percent second-quarter revenue growth on July 30, 2026.
Adjusted earnings per share increased 17.90 percent in the second quarter of 2026.
Stryker stock costs EUR 273.20 at Lang & Schwarz on October 26, 2026, down 0.69 percent versus the Xetra close.
Stryker's next earnings call is scheduled for October 29, 2026.

Stryker Corp., US8636671013, Illustration mit AI erstellt.

Stryker Corp. (ISIN US8636671013) reported second-quarter 2026 revenue growth of 9.40 percent to USD 6.59 billion, according to Ticker Scout on October 2, 2026, citing the company's filings. Adjusted earnings per share rose 17.90 percent to USD 3.69 in the quarter ended June 30, 2026. At Lang & Schwarz after the Xetra close on October 26, 2026 at 5:06 p.m. CEST, Stryker traded at EUR 273.20, down 0.69 percent versus the Xetra close of October 23, 2026.

Revenue growth outpaced the prior year

The second-quarter expansion came with a sharp earnings improvement. Reported net earnings increased 44.30 percent to USD 1.28 billion, while adjusted operating margin rose 170 basis points to 27.40 percent. The comparison benefited partly from a USD 158 million tariff reversal and lower amortization of inventory stepped up to fair value, factors identified in the filing summary.

What does the target imply?

BTIG lowered its Stryker price target to USD 316.00 from USD 358.00 on October 12, 2026, while keeping a Buy rating, Markets Insider reported. The primary-market quote was USD 305.13 on the NYSE at 12:12 p.m. ET on October 26, 2026, placing the stock 3.44 percent below that target.

Results arrive October 29

Stryker's next earnings call is scheduled for October 29, 2026, at 4:30 p.m. ET, according to the company's investor calendar at Stryker. The event will give investors a fresh test of the recovery following the first-quarter operational disruption and of the company's 2026 adjusted earnings-per-share outlook of USD 14.95 to USD 15.10.

Market value and trading range

Stryker's primary-market quote of USD 305.13 leaves it between a 52-week low of USD 267.00 and a high of USD 389.33, both dated October 26, 2026. Its market capitalization was USD 117.0 billion, and its price-to-earnings ratio was 31.62 on the same date. Medtronic had a USD 121.0 billion market capitalization and a 23.30 price-to-earnings ratio, while Becton, Dickinson and Company had USD 53.3 billion and a 58.91 ratio.

Stock position after the Xetra close

The EUR 273.20 Lang & Schwarz quote is EUR 1.90 below the EUR 275.10 Xetra close from October 23, 2026. The move is modest beside the company's reported second-quarter growth, leaving the upcoming results call as the next dated event for the stock.

The further course of trading is shown by the continuously updated real-time quote of Stryker stock.